Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model

被引:11
作者
Deshmukh, Deepali D. [1 ,2 ]
Nagilla, Rakesh [2 ,3 ]
Ravis, William R. [2 ]
Betageri, Guru V. [4 ]
机构
[1] GlaxoSmithKline Inc, Early Dev Grp Pharmaceut Dev, Collegeville, PA 19426 USA
[2] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA
[3] GlaxoSmithKline Inc, Preclin Drug Discovery, Discovery & Translat Biol, Pattern Recognit Receptors Discovery Performance, King Of Prussia, PA 19406 USA
[4] Western Univ Hlth Sci, Pomona, CA 91766 USA
关键词
BCS III; dodecylmaltoside; permeation enhancer; Caco-2; everted intestinal sacs; ABSORPTION ENHANCERS; DRUG TRANSPORT; PARACELLULAR TRANSPORT; IN-VITRO; LINE CACO-2; PHENOL RED; MONOLAYERS; PERMEABILITY; INSULIN; CULTURE;
D O I
10.3109/10717541003604882
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of n-lauryl-beta-D-maltopyranoside, (dodecylmaltoside, DDM) as a permeability-enhancer for tiludronate and cromolyn (BCS Class III, water-soluble compounds with oral bioavailability < 5%) was evaluated in Caco-2 cell monolayers and rat intestinal sacs. In Caco-2 cells samples were collected over a 5-h period and transepithelial resistance (TEER) was measured concurrently. In rat intestinal sacs, samples of the test compounds and marker (Lucifer Yellow) were collected over a 40 min period; accumulation in the serosal fluid and intestinal tissue was measured. At lower concentration DDM had no effect on cromolyn permeability and a marginal increase was observed at higher concentration. Tiludronate permeability in the presence of DDM showed greater enhancement as compared to cromolyn. At higher concentration DDM appeared to cause permanent damage to the cell monolayer (irreversible change in TEER). In the intestinal tissue, DDM caused increased tissue accumulation of test compounds. This indicated that transport was not restricted to the paracellular route and damage to the intestinal tissue could not be ruled out. Based on the results obtained in this study it can be concluded that at concentrations that are non-toxic DDM appears to have a limited use to improve the oral absorption of cromolyn and tiludronate.</.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 29 条
[1]  
Allen A., 1981, PHYSL GASTROINTESTIN, P617
[2]  
ANDERSON JM, 1995, AM J PHYSIOL, V269, P467
[3]   Caco-2 monolayers in experimental and theoretical predictions of drug transport [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 22 (1-2) :67-84
[4]   SITE-DEPENDENCE AND STRUCTURE-EFFECT RELATIONSHIPS FOR ALKYLGLYCOSIDES AS TRANSMUCOSAL ABSORPTION PROMOTERS FOR INSULIN [J].
AUNGST, BJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 105 (03) :219-225
[5]   An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine [J].
Barthe, L ;
Woodley, JF ;
Kenworthy, S ;
Houin, G .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (02) :313-323
[6]   IMPORTANCE OF THE PARACELLULAR PATHWAY FOR THE TRANSPORT OF A NEW BISPHOSPHONATE USING THE HUMAN CACO-2 MONOLAYERS MODEL [J].
BOULENC, X ;
MARTI, E ;
JOYEUX, H ;
ROQUES, C ;
BERGER, Y ;
FABRE, G .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (09) :1591-1600
[7]   SODIUM LAURYL SULFATE INCREASES TILUDRONATE PARACELLULAR TRANSPORT USING HUMAN EPITHELIAL CACO-2 MONOLAYERS [J].
BOULENC, X ;
BREUL, T ;
GAUTIER, JC ;
SAUDEMON, P ;
JOYEUX, H ;
ROQUES, C ;
BERGER, Y ;
FABRE, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 123 (01) :71-83
[8]   Disposition of tiludronate (Skelid®) in animals [J].
Davi, H ;
Tronquet, C ;
Caix, J ;
Simiand, J ;
Briot, C ;
Berger, Y ;
Thiercelin, JF .
XENOBIOTICA, 1999, 29 (10) :1017-1031
[9]  
Delie F, 1997, CRIT REV THER DRUG, V14, P221
[10]  
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736